EAM Investors’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

EAM Investors’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-81,642	Closed	-$2.17M	–	425
2017 Q1	$2.17M	Hold	81,642	–	–	0.34%	152
2016 Q4	$1.81M	Buy	+81,642	New	+$1.53M	0.24%	209
2015 Q4	–	Sell	-36,686	Closed	-$758K	–	409
2015 Q3	$758K	Buy	+36,686	New	+$752K	0.12%	281

Other funds holding NDRM

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

EAM Investors's NDRM Position: Q2 2017 in Review

EAM Investors sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q2 2017, closing a stake of 81,642 shares — an estimated $2.17M sold.

EAM Investors first reported a position in NDRM in Q3 2015 and held it in 3 quarters. The position peaked at $2.17M in Q1 2017. 73 funds tracked by Wall St. Rank hold NDRM as of Q2 2017.

EAM Investors reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
EAM Investors sold 81,642 NeuroDerm Ltd. Ordinary Shares shares in Q2 2017, an estimated $2.17M.
EAM Investors first reported a position in NeuroDerm Ltd. Ordinary Shares in Q3 2015 and held it in 3 quarters.
EAM Investors's NeuroDerm Ltd. Ordinary Shares position peaked at $2.17M in Q1 2017.
73 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q2 2017.

Based on EAM Investors's 13F filing for Q2 2017, filed 11 Aug 2017.